TP53 and lung cancer: A new molecular barcode technique identified other PIK3CA, TP53, KRAS, and MAP2K1 variants in EGFR TKI-resistant patients, demonstrating that the resistance mechanism involves not just EGFR T790M but also other variants in lung cancer patients [48].